BXP price target lowered to $78 from $80 at BMO Capital

BMO Capital analyst John Kim lowered the firm’s price target on BXP to $78 from $80 but keeps an Outperform rating on the shares after meeting with its management. Despite significant availability in the Boston life sciences market, the company’s market focus provides some defensiveness, the analyst tells investors in a research note. The firm further noted that BXP characterizes slow demand from early-stage biotech companies as temporary, with AI allowing for fewer scientists until bench work is required.